Compare ITG & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITG | BBOT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.6M | 682.5M |
| IPO Year | 2026 | N/A |
| Metric | ITG | BBOT |
|---|---|---|
| Price | $12.08 | $8.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 450.5K | 359.5K |
| Earning Date | N/A | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.37 | $7.00 |
| 52 Week High | $16.00 | $14.87 |
| Indicator | ITG | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 53.33 |
| Support Level | $10.37 | $7.99 |
| Resistance Level | $14.40 | $9.48 |
| Average True Range (ATR) | 1.52 | 0.57 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 41.50 | 45.21 |
ITG Inc provides services to the digital and other utility infrastructure industries throughout the United States. Its services support the planning, design, construction, operation, maintenance, and expansion of broadband and other infrastructure networks. It operates through two complementary service lines: i) Engineering & Maintenance: It provides re-occurring, mission-critical services required by network owners to operate, maintain, optimize and expand their infrastructure. ii) Infrastructure Deployment. It provides large-scale network and fiber construction services for incumbent carriers, overbuilders, and data center operators and underground civil construction services for public and private utilities. The majority of revenue is derived from the Engineering & Maintenance services.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.